deltatrials
Unknown PHASE4 INTERVENTIONAL 4-arm NCT05065892

Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes

A Post-marketing Clinical Study of the Inactivated SARS-CoV-2 Vaccine (Vero Cells) (Produced in Wuhan): Immunogenicity and Safety Assessments in Patients With Hypertension and/or Diabetes

Sponsor: Center for Disease Control and Prevention, Fujian

Conditions COVID-19 Pneumonia
Interventions COVAX
Updated 6 times since 2021 Last updated: Oct 16, 2021 Started: Oct 31, 2021 Primary completion: Jan 31, 2022 Completion: Mar 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05065892, this PHASE4 trial focuses on COVID-19 Pneumonia and remains ongoing. Sponsored by Center for Disease Control and Prevention, Fujian, it has been updated 6 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Nov 2021 – ~Nov 2022 · 12 months · monthly snapshotNot Yet Recruiting~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Nov 2023 · 9 months · monthly snapshotNot Yet Recruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE4

    Status: Unknown Status → Unknown

  3. Nov 2023 — Jul 2024 [monthly]

    Unknown Status PHASE4

    Status: Not Yet Recruiting → Unknown Status

  4. Feb 2023 — Nov 2023 [monthly]

    Not Yet Recruiting PHASE4

  5. Nov 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE4

▶ Show 1 earlier version

  1. Nov 2021 — Nov 2022 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Center for Disease Control and Prevention, Fujian
  • China National Biotec Group Company Limited
  • Guizhou Center for Disease Control and Prevention
  • Hunan Provincial Center for Disease Control and Prevention
  • Wuhan Institute of Biological Products Co., Ltd
Data source: China National Biotec Group Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations